Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study

Blood

Volumn 94, Issue 3, 1999, Pages 1086-1099

  Leith, Catherine P ^a   Kopecky, Kenneth J ^b   Chen, I Ming ^b   Eijdems, Lisette ^b   Slovak, Marilyn L ^b   McConnell, Thomas S ^b   Head, David R ^b   Weick, James ^b   Grever, Michael R ^b   Appelbaum, Frederick R ^b   Willman, Cheryl L ^b  

^a Southwest Oncology Group   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AGING; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DRUG TRANSPORT; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; GENE FREQUENCY; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROGNOSIS; TREATMENT OUTCOME; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0033179095     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Champlin R, Gale RP: Acute myelogenous leukemia: Recent advances in therapy. Blood 69:1551, 1987
2. Estey EH, Kantarjian H, Keating MJ: Therapy for acute myeloid leukemia, in Hoffman R, Benz EJ, Shatil S, Furie B, Cohen HJ, Silberstein LE (eds): Hematology: Basic Principles and Practice. New York, NY, Churchill Livingstone, 1995, p 1014
3. Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ: Principal results of the Medical Research Council's 8th acute myeloid leukemia trial. Lancet 2:1236, 1986
4. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652, 1993
5. Marie JP, Bastie JN, Coloma F, Suberville AF, Delmer A, Rio B, Delmas-Marsalet B, Leroux G, Casassus P, Baumelou E, Catalin J, Zittoun R: Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 7:821, 1993
6. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resisitance in patients with refactory myeloma: A Southwest Oncology Group study. Cancer 75:815, 1995
7. List AF, Kopecky KJ, Willman CL, Spier C, Dorr R, Appelbaum F, Hynes H: Benefit of Cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study. Blood 92:312a, 1999 (abstr, suppl 1)
8. Leith CP, Kopecky KJ, Godwin JE, McConnell T, Slovak M, Chen IM, Head DR, Appelbaum F, Willman CL: Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323, 1997
9. Zochbauer S, Gsur A, Brunner R, Kryle PA, Lechner K, Pirker R: P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 8:974, 1994
10. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473, 1992
11. Wood P, Burgess R, MacGregor A, Liu JA: P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 87:509, 1994
12. Musto P, Melillo L, Lombardi G, Matera R, DiGiorgio G, Carotenuto M: High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 77:50, 1991
13. Guerci A, Merlin JL, Missoum N, Feldman L, Marchal S, Witz F, Rose C, Guerci O: Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 8:2147, 1995
14. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfher M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K: MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708, 1991
15. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650, 1992
16. Zaman GJR, Lankelma J, Telligen O, Beijnen J, Dekker H, Paulusma C, Elferink R, Baas F, Borst P: Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 92:7690, 1995
17. Loe DW, Deeley RG, Cole SPC: Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A:945, 1996
18. Muller M, Meijer CJ, Zaman GJR, Borst P, Scheper RJ, Mulder HS, DE Vries EGE, Jansen PLM: Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91:13033, 1994
19. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P: Analysis of expression of cMOAT(MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res vol 57, 1997
20. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clever HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med 1:578, 1995
21. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS: Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2464, 1996
22. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager U, Geissler K, Lechner K, Pirker R: Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91:1508, 1998
23. Filipits M, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R: Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome. Clin Cancer Res 3:1419, 1997
24. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufman SH: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186, 1995
25. Ross DD, Doyle LA, Schiffer CA, Lee EJ, Grant CE, Cole SPC, Deeley RG, Yang W, Tong Y: Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia 10:48, 1996
26. Schuurhuis GJ, Broxterman HJ, Ossenkopplel GJ, Baak JP, Eekman CA, Kuiper CM, Feller N, Can Heijningen THM, Klumper E, Pieters R, Lankelma J, Pinedo HM: Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-B-D-arabinofuranosylcyostine may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1:81, 1995
27. Hart SM, Ganeeshaguuru K, Hoffbrand AV, Prentice HG, Mehta AB: Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia 8:2163, 1994
28. Legrand O, Simonin G, Perrot J, Zittoun R, Marie JP: Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91:4480, 1991
29. Weick JK, Kopecky KJ, Appelbaum F, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M: A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 88:2841, 1996
30. Head D, Cerezo L, Savage RA, Craven CM, Bickers JN, Hartsock R, Hosty TA, Saiki JH, Wilson HE, Morrison FS, Coltman CA, Hutton JJ: Institutional performance in application of the FAB classification of acute leukemia, the Southwest Oncology Group experience. Cancer 55:1979, 1985
31. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL: Correlation of multidrug resistance-(MDR1) protein expression with functional dye-drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant CD34+/MDR1-Efflux+and MDR1+/Efflux-cases. Blood 86:2329, 1995
32. Dalton WS, Durie BGM, Alberts DS, Gerlach JH, Cress AE: Characterization of a new drug-resistant human myeloma cell line that expressed p-glycoprotein. Cancer Res 46:1986
33. Futscher B, Abbaszadegan MR, Somann F, Dalton WS: Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharmacol 47:1601, 1994
34. Zaman GJR, Flens MJ, VanLeusden MR, Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91:8822, 1994
35. Krishnamachary N, Center MS: The MRP gene associated with a non-P-glycoprotein multi-drug resistance encodes a 190-kDa membrane bound protein. Cancer Res 53:3658, 1993
36. 2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 25:14, 1999
37. Feller N, Kuiper CM, Lankelma J, Ruhdal JK, Scheper RJ, Pinedo HM, Broxterman HJ: Functional detection of MDR1/P170 and MRP P190-mediated multidrug resistance in tumor cells by flow cytometry. Br J Cancer 72:543, 1995
38. Essodaigui M, Broxterman HJ, Garnier-Suillerot A: Kinetic analysis of calcein and celcein-acetoxymethylester efflux mediated by the multidrug resistance protein and p-glycoprotein. Biochemistry 37:2243, 1998
39. Borowitz MJ, Bray R, Gascoyne RD, Melnick S, Parker JW, Picker L, Stetler-Stevenson M: US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data analysis and interpretation. Cytometry 30:236, 1997
40. Braylan RC, Atwater SK, Diamond L, Hassett JM, Johnson M, Kidd PG, Leith C, Nguyen D: US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data reporting. Cytometry 30:245, 1997
41. Young IT: Proof without prejudice: use of the Kolmogorov Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 25:935, 1997
42. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietl M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Kumar Srivastava D, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R: Methods to detect P-glycoprotein-associated multidrug resistance in patient tumors: Consensus recommendations. Cancer Res 56:3010, 1996
43. ICSN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
44. Neter J, Wasserman W: Applied Linear Statistical Models. Homewood, IL, Irwin, 1974
45. Cox DR: The Analysis of Binary Data. London, UK, Chapman and Hall, 1970
46. Kaplan EL, Meier P: Nonparametric estimate from incomplete observations. J Am Stat Assoc 53:457, 1958
47. Cox DR: Regression models and life tables (with discussion). J Royal Stat Soc B 34:187, 1972
48. Fourth International Workshop on Chromosomes in Leukemia: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet 11:332, 1998
49. Fenaux P, Preudhomme C, Lai JL, Morel P, Beuscart R, Bauters F: Cytogenetics and their prognostic value in de novo acute myeloid leukemia: A report on 283 cases. Br J Haematol 73:61, 1989
50. Arthur DC, Berger R, Golomb HM, Swansbury GJ, Reeves BR, Alimena G, Van Den Berghe H, Bloomfield CD, de la Chapelle A, Dewald GW, Garson OM, Hagemeijer A, Kaneko Y, Mitelman F, Pierre RV, Ruutu T, Sakurai M, Lawler SD, Rowley JD: The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 40:203, 1989
51. Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ: Toward a clinically relevant cytogentic classification of acute myelogenous leukemia. Leuk Res 11:119, 1987
52. Schiffer CA, Lee EJ, Takafumi T, Wiernick PH, Testa JR: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73:263, 1989
53. Yunis JJ, Lobell M, Arnesen MA, Oken MM, Mayer MG, Rydell RE, Brunning RD: Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 68:189, 1998
54. Lamy T, Drenou B, Grulois I, Fardel O, Jacquelinet C, Goasguen J, Dauriac C, Amiot L, Bernard M, Fauchet R, Le Prise PY: Multi-drug resistant (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 9:1549, 1995
55. Paietta E, Anderson J, Racevskis J, Gallagher R, Bennett J, Yunis J, Cassileth P, Wiernick PH: Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analysis. Leukemia 8:968, 1994
56. Head D, Kopecky KJ, Weick S, Files J, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Wellborn J, Williams W, Hewlett J, Willman C, Appelbaum F: Effect of aggresive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717, 1995
57. Michieli M, Damiani D, Ermacora A, Raspadori D, Michelutti A, Grimaz S, Fanin R, Russo D, Lauria F, Masolini P, Baccarani M: P-glycoprotein (PGP) and lung resistant related protein (LRP) expression and function in leukaemic blast cells. Br J Haematol 96:356, 1997
58. Legrand O, Simonin G, Zittoun R, Marie J-P: Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: A critical evaluation by three techniques. Leukemia 12:1367, 1998
59. Doyle LA, Yang W, Ahmann GJ, Krogmann T, Gao Y, Rishi AK, Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665, 1998
60. Connors TD, Van Raay TJ, Petry LR, Klinger KW, Landes GM, Burn TC: The cloning of a human ABC gene (ABC3) mapping to chromosome 16p13.3. Genomics 39:231, 1997
61. Luciani MF, DFSSMMCG: Cloning of two novel ABC transporters mapping on human chromosome 9. Genomics 21:150, 1994
62. List AF, Glinsmann-Gibson B, Heaton R, Schlegel S, Guzman M, Futscher B: Cyclosporines (CS) inhibit interleukin-1B (L-1B) secretion by the ABC1 transporter, impair leukemia self-renewal and sensitize AML progenitors to antineoplastics. Blood 92:675a, 1998 (abstr, suppl 1)
63. Burger H, Nooter K, Zaman GJR, Sonneveld P, Van Wingerden KE, Olstrum RG, Stoter G: Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 8:990, 1994
64. Nooter K, Westerman AM, Flens MJ, Zaman GJR, Scheper RJ, Van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, Grattama JW, Kok T, Eggermont AMM, Bosman FT, Stoter G: Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1:1301, 1995
65. Zhou DC, Zittoun R, Marie JP: Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 9:1661, 1995